Liza Villaruz
机构: Assistant Professor, University of Pittburgh
每年引用次数
引用次数
引用: 6,452
H-指数: 31
I10-指数 : 56
出版物: 150
Phase I/II trial of healthy donor fecal microbiota transplant (hdFMT) in PD-1 relapsed/refractory (R/R) non-small cell lung cancer (NSCLC).
Timothy F Burns , Hong Wang , Drew Hurd , Madison Nguyen
Journal of Clinical Oncology 42 ( 16_suppl) TPS8648 -TPS8648
2024
Berzosertib plus topotecan vs topotecan alone in patients with relapsed small cell lung cancer: a randomized clinical trial
Nobuyuki Takahashi , Zhonglin Hao , Liza C Villaruz , Jun Zhang
JAMA oncology 9 ( 12) 1669 -1677
9
2023
Efficacy of ATR inhibitor berzosertib plus topotecan or topotecan alone in patients with relapsed small cell lung cancer: A randomized clinical trial
Nobuyuki Takahashi , Zhonglin Hao , Liza C Villaruz , Jun Zhang
MOLECULAR CANCER THERAPEUTICS 22 ( 12)
2023
Abstract LB_A10: Efficacy of ATR inhibitor berzosertib plus topotecan or topotecan alone in patients with relapsed small cell lung cancer: A randomized clinical trial
Nobuyuki Takahashi , Zhonglin Hao , Liza C Villaruz , Jun Zhang
Molecular Cancer Therapeutics 22 ( 12_Supplement) LB_A10 -LB_A10
2023
Evaluation of the genomic and immune profiles of patients with lung adenosquamous carcinoma (LUAS) and association of response to treatment.
Matthew Lee , Tolulope Tosin Adeyelu , Shuai Wang , Andrew Elliott
Journal of Clinical Oncology 42 ( 16_suppl) 8567 -8567
2024
A phase 1 dose-escalation and expansion study of an intratumorally administered dual STING agonist (ONM-501) alone and in combination with cemiplimab in patients with advanced solid tumors and lymphomas.
Julia Foldi , Sarina A Piha-Paul , Liza C Villaruz , Heather L McArthur
Journal of Clinical Oncology 42 ( 16_suppl) TPS2693 -TPS2693
2024
Combination of itacitinib or parsaclisib with pembrolizumab in patients with advanced solid tumors: a phase i study
Pamela Munster , Nicholas Iannotti , Daniel C Cho , John M Kirkwood
Cancer Research Communications 3 ( 12) 2572 -2584
4
2023
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
Aaron Scott Mansfield , Austin Goodrich , Nathan R Foster , Vinicius Ernani
Journal of Clinical Oncology 40 ( 16_suppl) TPS8598 -TPS8598
1
2022
Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Pamela Munster , Nicholas Iannotti , Daniel C Cho , John M Kirkwood
Cancer Research Communications 4 ( 3) 785 -785
2024
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
Aaron Scott Mansfield , Austin Goodrich , Nathan R Foster , Panos Savvides
Journal of Clinical Oncology 41 ( 16_suppl) TPS8603 -TPS8603
2023
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Liza C Villaruz , Manuel Cobo , Konstantinos Syrigos , Dimitrios Mavroudis
Lung Cancer 136 52 -56
2
2019
Macrovasculature and positron emission tomography (PET) standardized uptake value in patients with lung cancer
Jiantao Pu , Joseph K Leader , Dongning Zhang , Cameron A Beeche
Medical physics 48 ( 10) 6237 -6246
1
2021
Overcoming KRAS-mutant lung cancer
Jia Luo , Jonathan Ostrem , Bruna Pellini , Denis Imbody
American Society of Clinical Oncology Educational Book 41 700 -710
22
2022
A Phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy-naive incurable stage IIIb/IV non-squamous non-small cell lung cancer.
Juneko E Grilley-Olson , Liza C Villaruz , Thomas E Stinchcombe , Jared Weiss
MOLECULAR CANCER THERAPEUTICS 12 ( 11)
2013
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma
Aaron S Mansfield , Jun Vivien Yin , Penelope Bradbury , David J Kwiatkowski
Lung Cancer 107928 -107928
2024
Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine
Liza C Villaruz , Mark A Socinski , Jared Weiss
Frontiers in Oncology 13 1124167 -1124167
18
2023
A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).
Jonathan W Riess , Mary Weber Redman , Paul Wheatley-Price , Bryan A Faller
Journal of Clinical Oncology 39 ( 15_suppl) 9024 -9024
10
2021
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2
Khvaramze Shaverdashvili , Vincent Reyes , Hong Wang , Dhaval Mehta
EClinicalMedicine 66
1
2023
Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).
Karen L Reckamp , Mary Weber Redman , Konstantin H Dragnev , Liza C Villaruz
Journal of Clinical Oncology 39 ( 15_suppl) 9075 -9075
1
2021
Tackling KRASG12C-mutated non-small-cell lung cancer: iteration and exploration
Jia Luo , Liza C Villaruz
The Lancet Respiratory Medicine
2024